Discontinuation of inhaled corticosteroids in COPD and the risk reduction of pneumonia

Chest

Volumn 148, Issue 5, 2015, Pages 1177-1183

  Suissa, Samy ^a,b   Coulombe, Janie ^b   Ernst, Pierre ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FLUNISOLIDE; FLUTICASONE; LONG ACTING DRUG; SHORT ACTING DRUG; TRIAMCINOLONE; GLUCOCORTICOID;

AGE DISTRIBUTION; AGED; ARTICLE; CANADA; CASE CONTROL STUDY; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DEATH; DISEASE SEVERITY; DRUG SAFETY; DRUG WITHDRAWAL; FACTUAL DATABASE; FEMALE; FOLLOW UP; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PRESCRIPTION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK REDUCTION; SEX DIFFERENCE; TREATMENT DURATION; CLINICAL TRIAL; INCIDENCE; INHALATIONAL DRUG ADMINISTRATION; MULTICENTER STUDY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDY; RISK ASSESSMENT; TIME; TREATMENT WITHDRAWAL;

ADMINISTRATION, INHALATION; AGED; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; INCIDENCE; MALE; PNEUMONIA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUEBEC; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TIME FACTORS; WITHHOLDING TREATMENT;

EID: 84945220326     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.15-0627     Document Type: Article

References (18)

1. Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013; 187 (4): 347-365.
2. Izquierdo JL, Martín A, de Lucas P, Rodríguez-González-Moro JM, Almonacid C, Paravisini A. Misdiagnosis of patients receiving inhaled therapies in primary care. Int J Chron Obstruct Pulmon Dis. 2010; 5: 241-249.
3. Corrado A, Rossi A. How far is real life from COPD therapy guidelines? An Italian observational study. Respir Med. 2012; 106 (7): 989-997.
4. Roche N, Pribil C, Van Ganse E, et al. Real-life use of fluticasone propionate/salmeterol in patients with chronic obstructive pulmonary disease: a French observational study. BMC Pulm Med. 2014; 14: 56.
5. Rossi A, van der Molen T, del Olmo R, et al. INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD. Eur Respir J. 2014; 44 (6): 1548-1556.
6. Magnussen H, Disse B, Rodriguez-Roisin R, et al; WISDOM Investigators. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014; 371 (14): 1285-1294.
7. Calverley PM, Anderson JA, Celli B, et al; TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007; 356 (8): 775-789.
8. Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med. 2007; 176 (2): 162-166.
9. Dransfield MT, Bourbeau J, Jones PW, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med. 2013; 1 (3): 210-223.
10. Suissa S, Patenaude V, Lapi F, Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2013; 68 (11): 1029-1036.
11. Garbe E, LeLorier J, Boivin JF, Suissa S. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or openangle glaucoma. JAMA. 1997; 277 (9): 722-727.
12. Garbe E, Suissa S, LeLorier J. Association of inhaled corticosteroid use with cataract extraction in elderly patients [published correction appears in JAMA 1998;280(21):1830]. JAMA. 1998; 280 (6): 539-543.
13. Ernst P, Baltzan M, Deschênes J, Suissa S. Low-dose inhaled and nasal corticosteroid use and the risk of cataracts. Eur Respir J. 2006; 27 (6): 1168-1174.
14. Suissa S, Baltzan M, Kremer R, Ernst P. Inhaled and nasal corticosteroid use and the risk of fracture. Am J Respir Crit Care Med. 2004; 169 (1): 83-88.
15. Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med. 2010; 123 (11): 1001-1006.
16. Wilchesky M, Tamblyn RM, Huang A. Validation of diagnostic codes within medical services claims. J Clin Epidemiol. 2004; 57 (2): 131-141.
17. Gershon AS, Wang C, Guan J, Vasilevska-Ristovska J, Cicutto L, To T. Identifying individuals with physcian diagnosed COPD in health administrative databases. COPD. 2009; 6 (5): 388-394.
18. Ernst P, Saad N, Suissa S. Inhaled corticosteroids in COPD: the clinical evidence. Eur Respir J. 2015; 45 (2): 525-537.